MA-ASTADIA
23.3.2021 15:02:11 CET | Business Wire | Press release
In today’s environment, many organizations have a “Cloud First” strategy for deploying business applications. Since most of the important business applications reside on mainframes, moving these applications and databases to any Cloud platform requires expert skills and technology.
The combination of Astadia’s Replatforming solutions, plus the Anubex Refactoring capabilities, offers a complete mainframe migration RoadMap. Astadia now offers all solution sets required to migrate from any IBM Z Series, or Unisys ClearPath platform, to the Cloud platform of their choosing.
“This is an exciting time to be in the Mainframe Migration business. The rapidly shrinking pool of people with mainframe software and hardware skills has given a new sense of urgency to IT buyers. The shortage of these critical skills is exacerbated by the COVID-19 Pandemic,” said Scott G. Silk, Chairman and CEO of Astadia.
“With this wave of Cloud computing, organizations are rapidly moving their applications and databases from mainframes. The Cloud enables incredible software innovation and developer productivity, access to AI and Predictive Analytics, while only charging the client for the resources they consume,” said Mr. Silk.
“Combining the forces of Astadia and Anubex leads to a unique combination of sales and delivery power with an exceptional portfolio of solutions for the migration market. This team is ready to accompany the largest organizations on their journey to the Cloud and becomes an important player in the top tier of mainframe migration companies,” said Louis Heymans, Managing Director of Anubex.
The acquisition of Anubex by Astadia allows the Anubex R&D team to continue to focus on extending their portfolio of products (CodeTurn, DataTurn, TestMatch and DataMatch) to automate refactoring and testing of legacy systems. The development of these products started well over 20 years ago, and today includes legacy technologies such as Assembler, COBOL, IDMS and Natural ADABAS that can be migrated to, among others, Java or C# in combination with all the leading SQL-databases – with the resulting applications ready for deployment in the (public) Cloud. These solutions using a Cloud-based “Migration Factory” model will be available to Astadia partners and clients worldwide.
For more details, take advantage of Astadia’s FREE Mainframe-to-Cloud Modernization Guide series, where we assist our clients as they plan and move into a safe and secure, high performance, cloud environment. This series covers IBM (NYSE:IBM) and UNISYS (NYSE:UIS) mainframes, and all popular target Cloud Platforms.
In these Mainframe-to-Cloud Migration Guides , readers will explore 20 pages of:
- Why migrate mainframe applications & databases to the Cloud?
- The challenges associated with mainframe modernization
- Detailed diagrams of mainframe software mappings to Cloud Platforms
- Programming languages & database translation tables
The Mainframe-to-Cloud Guide series is FREE , and may be downloaded.
Click on this link to view the Astadia Mainframe-to-Cloud Modernization Guide Series.
For more information visit http://www.astadia.com and follow Astadia at @AstadiaInc , Facebook/AstadiaInc , LinkedIn/Astadia
About Anubex
Anubex is an industry leader providing core software solutions, know-how, and support for complex mainframe-to-cloud migration and modernization projects.
With over 25 years of experience, demonstrated solutions and high-performing software tools, we help enterprises and government organizations boost their innovation capacity, competitiveness and agility by accelerating their digital transformation.
We are migration specialists, independent of the legacy or target technology stack. Our core competence lies in the know-how, the unique software solutions, and the extensive experience in how complex migration projects should be undertaken: what the stages and steps are, how the project should be structured, what the typical pitfalls and risks are, and how processes should be automated.
Our automated conversion and testing tools , combined with an innovative migration methodology , enable our team to support complex modernization projects and be one of the most competitive and reliable migration companies in the world.
Contacts / Headquarters
www.anubex.com
Anubex HQ
Anubex NV
Veldkant 13
2550 Kontich
Belgium
+32 3 450 42 50
migrations@anubex.com
About Astadia
Astadia is the market leading mainframe modernization consulting and systems integration boutique. A worldwide IT consulting firm, we specialize in moving IBM and Unisys mainframe applications and databases to distributed and cloud platforms. In fact, we were recently named Microsoft’s Mainframe-to-Azure partner of the year. Clients select Astadia for the following reasons: mainframe to cloud market focus, 28 years of mainframe experience, and hybrid READI methodology. Upon project completion, customers often select Astadia to manage their cloud environment as well. We have successfully completed over 200 mainframe modernization projects and are recognized industrywide as the mainframe to cloud experts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom